Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 9, 2005, Pages 951-960

  Di Caro, Simona ^a,b   Tao, Hong ^b   Grillo, Antonino ^a   Franceschi, Francesco ^a   Elia, Chiara ^a   Zocco, Maria Assunta ^a   Gasbarrini, Giovanni ^a   Sepulveda, Antonia R ^b   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bacillus clausii; Gene expression profiles; Intestinal mucosa; Microarray analysis

Indexed keywords

ESOMEPRAZOLE; PROBIOTIC AGENT;

ADULT; APOPTOSIS; ARTICLE; BACILLUS; BACILLUS CLAUSII; BACTERIAL FLORA; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL ARTICLE; DNA MICROARRAY; DUODENUM BIOPSY; ENDOSCOPY; GENE EXPRESSION PROFILING; GENE TARGETING; HOST PARASITE INTERACTION; HUMAN; MALE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SMALL INTESTINE MUCOSA;

ADULT; BACILLUS; CELL PHYSIOLOGY; ESOPHAGITIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MICROARRAY ANALYSIS; ORGANIC CHEMICALS; POLYMERASE CHAIN REACTION; PROBIOTICS;

EID: 23944492119     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200509000-00011     Document Type: Article

References (48)

1. Vanderhoof JA. Probiotics: future directions. Am J Clin Nutr 2001; 73:1152S-1155S.
2. Tuomola E, Crittender R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001; 73 (2 suppl): 393S-398S.
3. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16:658-672.
4. Koheler H, McCornick BA, Walker WA. Bacterial-enterocyte crosstalk: cellular mechanisms in health and disease. J Pediatr Gastroenterol Nutr 2003; 36:175-185.
5. Lu L, Walker WA. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. Am J Clin Nutr 2001; 73:1124S-1130S.
6. Bozdogan B, Galopin S, Leclercq R. Characterization of a new erm-related macrolide resistance gene present in probiotic strains of Bacillus clausii. Appl Environ Microbiol 2004; 70:280-284.
7. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004; 20:1181-1188.
8. Bozdogan B, Galopin S, Gerbaud G, Courvalin P, Leclercq R. Chromosomal aadD2 encodes an aminoglycoside nucleotidyltransferase in Bacillus clausii. Antimicrob Agents Chemother 2003; 47:1343-1346.
9. Senesi S, Celandroni F, Tavanti A, Ghelardi E. Molecular characterization and identification of Bacillus clausii strains marketed for use in oral bacteriotherapy. Appl Environ Microbiol 2001; 67:834-839.
10. Ducle H, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004; 70:2161-2171.
11. Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol 2004; 38 (6 suppl):S86-S90.
12. Ciprandi G, Tosca MA, Milanese M, Caligo G, Ricca V. Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: a pilot study. Pediatr Allergy Immunol 2004; 15:148-151.
13. Wu TD. Analysing gene expression data from DNA microarrays to identify candidate genes. J Pathol 2001; 195:53-65.
14. Kaminski N, Friedman N. Practical approaches to analysing results of microarray experiments. Am J Respir Cell Mol Biol 2002; 27:125-132.
15. Dennis GJ, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4(5):P3. Epub 2003 Apr 3.
16. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361:512-519.
17. Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. J Nutr 2000; 130 (suppl 2):S403-S409.
18. Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminem S. Probiotics: effects on immunity. Am J Clin Nutr 2001; 73 (suppl 2):S444-S450.
19. O'Neil DA. Regulation of expression of beta-defensins: endogenous enteric peptide antibiotics. Mol Immunol 2003; 40:445-450.
20. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003; 9: 215-223.
21. Onami TM, Harrington LE, Williams MA, Galvan M, Larsen CP, Pearson TC, et al. Dynamic regulation of T cell immunity by CD43. J Immunol 2002; 168:6022-6031.
22. Perdigon G, Maldonado Galdeano C, Valdez JC, Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 2002; 56 (suppl 4):S21-S26.
23. Meltzer EO. The role of the immune system in the pathogenesis of asthma and an overview of the diagnosis, classification, and current approach to treating the disease. J Manag Care Pharm 2003; 9 (5 suppl):8-13.
24. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20.
25. Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J, et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 2002; 169:1760-1767.
26. Waldmann T. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res 2002; (4 suppl 3):S161-S167. E-pub 9 May 2002.
27. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111:677-690.
28. Homaidan FR, Chakroun I, El-Sabban ME. Regulation of nuclear factor-kappaB in intestinal epithelial cells in a cell model of inflammation. Mediators Inflamm 2003; 12:277-283.
29. Burke JR. Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Dev 2003; 6:720-728.
30. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22:8961-8982.
31. Homaidan FR, Chakroun I, El-Sabban ME. Regulation of nuclear factor-kappaB in intestinal epithelial cells in a cell model of inflammation. Mediators Inflamm 2003; 12:277-283.
32. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 2003; 201:28-36.
33. Sasaki M, Bharwani S, Jordan P, Elrod JW, Grisham MB, Jackson TH, et al. Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radic Biol Med 2003; 35:1679-1687.
34. Van Den Blink B, Ten Hove T, Van Den Brink GR, Peppelenbosch MP, Van Deventer SJ. From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease. Ann NY Acad Sci 2002; 973: 349-358.
35. Goldsmith EJ, Cobb MH, Chang CI. Structure of MAPKs. Methods Mol Biol 2004; 250:127-144.
36. Chin L, Schreiber-Agus N, Pellicer I, Chen K, Lee HW, Dudast M, et al. Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci USA 1995; 92: 8488-8492.
37. Wang X, Guan J, Hu B, Weiss RS, Iliakis G, Wang Y. Involvement of Hus1 in the chain elongation step of DNA replication after exposure to camptothecin or ionizing radiation. Nucl Acids Res 2004; 32:767-775.
38. Nagayama S, Onodera H, Toguchida J, Imamura M. Altered expression of the receptor and ligand in the TGF beta signaling pathway in diffusely infiltrating colon carcinoma. Anticancer Res 2002; 22:3545-3554.
39. Itoh H, Kataoka H. Roles of hepatocyte growth factor activator (HGFA) and its inhibitor HAI-1 in the regeneration of injured gastrointestinal mucosa. J Gastroenterol 2002; 37 (suppl 14):15-21.
40. Sturm A, Schulte C, Schatton R, Becker A, Cario E, Goebell H, et al. Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12:445-450.
41. Arthur LG, Kuenzler KA, Schwartz MZ. Hepatocyte growth factor ameliorates inflammatory bowel disease in a rat model. J Gastrointest Surg 2003; 7:1062-1068.
42. Street ME, de' Angelis G, Camacho-Hubner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004; 61:159-164. E-pub 22 December 2003.
43. Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity 2003; 19:781-791.
44. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15:515-522.
45. Newton K, Strasser A. Caspases signal not only apoptosis but also antigen-induced activation in cells of the immune system. Genes Dev 2003; 17:819-825.
46. Hur K, Kim JR, Yoon BI, Lee JK, Choi JH, Oh GT, et al. Overexpression of cyclin D1 and cyclin E in 1,2-dimethylhydrazine dihydrochloride-induced rat colon carcinogenesis. J Vet Sci 2000; 1:121 -126.
47. Paul R, Necknig U, Busch R, Ewing CM, Hartung R, Isaacs WB. Cadherin-6: a new prognostic marker for renal cell carcinoma. J Urol 2004; 171: 97-101.
48. Bienz M. The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol 2002; 3:328-338.